» Articles » PMID: 33042810

Inflammasome Deletion Promotes Anti-tumor NK Cell Function in an IL-1/IL-18 Independent Way in Murine Invasive Breast Cancer

Overview
Journal Front Oncol
Specialty Oncology
Date 2020 Oct 12
PMID 33042810
Citations 8
Authors
Affiliations
Soon will be listed here.
Abstract

Inflammasomes are molecular complexes that trigger an inflammatory response upon detection of pathogens or danger signals. Recent studies suggest that they are also involved in cancer progression. However, their roles during tumorigenesis remain poorly understood and controversial. Here, we investigated whether inflammasome activation supports mammary tumor growth. Using mouse models of invasive breast cancer, our results demonstrate that the absence of a functional inflammasome impairs tumor growth. Importantly, tumors implanted into inflammasome-deficient mice recruited significantly less neutrophils and more natural killer (NK) cells, and these latter cells displayed a more active phenotype. Interestingly, NK cell depletion abolished the anti-tumoral effect observed in inflammasome-deficient mice, although inflammasome-regulated cytokine neutralization had no effect. Thus, our work identifies a novel role for the inflammasome in supporting mammary tumor growth by attenuating NK cell recruitment and activity. These results suggest that inflammasome inhibition could be a putative target for treating invasive breast cancers.

Citing Articles

Inhibition of NLRP3 inflammasome contributes to paclitaxel efficacy in triple negative breast cancer treatment.

Balahura Stamat L, Dinescu S Sci Rep. 2024; 14(1):24753.

PMID: 39433537 PMC: 11494052. DOI: 10.1038/s41598-024-75805-3.


Harnessing innate immune pathways for therapeutic advancement in cancer.

Hu A, Sun L, Lin H, Liao Y, Yang H, Mao Y Signal Transduct Target Ther. 2024; 9(1):68.

PMID: 38523155 PMC: 10961329. DOI: 10.1038/s41392-024-01765-9.


Divergent functions of NLRP3 inflammasomes in cancer: a review.

Shadab A, Mahjoor M, Abbasi-Kolli M, Afkhami H, Moeinian P, Safdarian A Cell Commun Signal. 2023; 21(1):232.

PMID: 37715239 PMC: 10503066. DOI: 10.1186/s12964-023-01235-9.


Pan-cancer analysis of prognostic and immunological role of DTYMK in human tumors.

Zhao H, Xie R, Zhang C, Lu G, Kong H Front Genet. 2022; 13:989460.

PMID: 36159971 PMC: 9493117. DOI: 10.3389/fgene.2022.989460.


Downstream Signaling of Inflammasome Pathway Affects Patients' Outcome in the Context of Distinct Molecular Breast Cancer Subtypes.

Saponaro C, Fanizzi A, Sonnessa M, Mondelli P, Vergara D, Loisi D Pharmaceuticals (Basel). 2022; 15(6).

PMID: 35745570 PMC: 9229152. DOI: 10.3390/ph15060651.


References
1.
Yazdi A, Drexler S, Tschopp J . The role of the inflammasome in nonmyeloid cells. J Clin Immunol. 2010; 30(5):623-7. DOI: 10.1007/s10875-010-9437-y. View

2.
Bunt S, Sinha P, Clements V, Leips J, Ostrand-Rosenberg S . Inflammation induces myeloid-derived suppressor cells that facilitate tumor progression. J Immunol. 2005; 176(1):284-90. DOI: 10.4049/jimmunol.176.1.284. View

3.
Boggio K, Nicoletti G, Di Carlo E, Cavallo F, Landuzzi L, Melani C . Interleukin 12-mediated prevention of spontaneous mammary adenocarcinomas in two lines of Her-2/neu transgenic mice. J Exp Med. 1998; 188(3):589-96. PMC: 2212479. DOI: 10.1084/jem.188.3.589. View

4.
Fridman W, Dieu-Nosjean M, Pages F, Cremer I, Damotte D, Sautes-Fridman C . The immune microenvironment of human tumors: general significance and clinical impact. Cancer Microenviron. 2012; 6(2):117-22. PMC: 3717061. DOI: 10.1007/s12307-012-0124-9. View

5.
Calogero R, Cordero F, Forni G, Cavallo F . Inflammation and breast cancer. Inflammatory component of mammary carcinogenesis in ErbB2 transgenic mice. Breast Cancer Res. 2007; 9(4):211. PMC: 2206718. DOI: 10.1186/bcr1745. View